1 – 6 of 6
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2023
-
Mark
The Lucerne Toolbox 2 to optimise axillary management for early breast cancer : a multidisciplinary expert consensus
(
- Contribution to journal › Scientific review
- 2020
-
Mark
Efficacy and safety of tailored and dose-dense adjuvant chemotherapy and trastuzumab for resected HER2-positive breast cancer : Results from the phase 3 PANTHER trial
(
- Contribution to journal › Article
-
Mark
Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer
(
- Contribution to journal › Article
-
Mark
Application of a risk-management framework for integration of stromal tumor-infiltrating lymphocytes in clinical trials
(
- Contribution to journal › Scientific review
-
Mark
The path to a better biomarker: application of a risk management framework for the implementation of PD‐L1 and TILs as immuno‐oncology biomarkers into breast cancer clinical trials and daily practice
(
- Contribution to journal › Scientific review
- 2016
-
Mark
Effect of tailored dose-dense chemotherapy vs standard 3-weekly adjuvant chemotherapy on recurrence-free survival among women with high-risk early breast cancer : A randomized clinical trial
(
- Contribution to journal › Article